Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. A phase II study

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 4151-4156

  Polyzos, Aristides ^a   Felekouras, Evangellos ^a   Karatzas, Theodore ^a   Griniatsos, John ^a   Dimitroulis, Dimitrios ^a   Polyzos, Kostas ^a   Kontzoglou, Kostas ^a   Mantas, Dimitrios ^a   Karavokyros, John ^a   Nikiteas, Nikolaos ^a   Tsavaris, Nikolas ^a   Syrigos, Kostas ^a   Vafiadis, Irene ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Advanced gastric carcinoma; Capecitabine; Cisplatin; Docetaxel; First line chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ONDANSETRON; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NEPHROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TAXOIDS;

EID: 84867003383     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ajani JA: Current status of therapy for advanced gastric cancer. Oncology 12(Suppl 6): 99-102, 1998.
2. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, Bunte H and Meyer J: Chemotherapy of gastric cancer. Cance Treat Rev 15: 257-277, 1988.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
4. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Boguel C, Lasser P, Ychou M and Elias D: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263-1269, 1994.
5. Kim NK, Park US, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin OB, Kim HT and Kim HJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
6. Stathopoulos GR, Rigatos SK, Fountzilas G, Polyzos A and Stathopoulos JG: Paclitaxel and carcoplatin in pretreated advanced gastric cancer: A phase II study. Oncol Rep 9: 89-92, 2002.
7. Mavroudis D, Kouroussis C, Androulakis N, Kalbakis K, Agelaki-Kakolyris S, Souglakos J, Sarra E, Vardakis N, Hatzidaki D, Samonis G and Georgoulias B: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial. Am J Clin Oncol 23: 341-344, 2000.
8. Roth AD, Maibach R, Martinelli G, Fazion N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M and Coldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11: 301-306, 2000.
9. Ridwelski K, Gebauer T, Fahlke J, Kröning H, Kettnez E, Meyer F, Eichelmann K and Lippert H: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12: 47-51, 2001.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Vozuyil E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
11. Ozdemir NY, Abali H, Oksuzoglou B, Budakoglu B, Uncu D, Guller T, Odabasi H and Zengin N: The efficacy and safety of reduced-dose docetaxel, cisplatin and 5-fluorouracil in the first line treatment of advanced stage gastric adenocarcinoma. Med Oncol 27: 680-684, 2010.
12. Kos FT, Uncu D, Ozdemir N, Budakoglu B, Odabas H, Abali H, Oksuzoglu B, Aksoyi S and Zengin N: Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Chemotherapy 57: 230-235, 2011.
13. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park NJ, Han JY, Kang JH, Lee KS and Cho JY: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15: 1344-1347, 2004.
14. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y and Taguchi T: A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64: 232-236, 2003.
15. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS and Lee JS: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13: 1893-1898, 2002.
16. Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, Kim BS and Kim TW: Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 657(6): 1435-1443, 2011.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wandedrs J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SC: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
19. Catalano V, Labianca R, Beretta DG, Gatta G, Braud de F and Cutsen VE: Gastric cancer. Crit Rev in Oncol/Hematol 71: 127-164, 2009.
20. Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Nazuke A and Katada C: A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69(2): 407-413, 2012.
21. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanishi K, Sato T, Takimodo R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y and Kato J: Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66(4): 721-728, 2010.
22. Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PWT, Yao JC and Feig BW: The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Cancer 113: 461-469, 2008.
23. Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos A, Michailidis G, Tendes A, Deftereos S, Karanikas M, Karayiannakis A and Kakolyris S: Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology 80(5-6): 359-365, 2011.
24. Polyzos A, Tsavaris N, Kosmas C, Polyzos K, Felekouras E, Nikiteas N, Kouraklis G, Griniatsos J, Safioleas M, Stamatakos M, Pikoulis E, Papachristodoulou A and Gogas H: Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel cisplatin. Anticancer Res 26: 3-7, 2006.
25. Kunisaki C, Imada T, Ymada R, Hatoris-Ono H, Otsuka Y, Matsuda G, Nomura M, Akiyama H, Kubo A and Shimada H: Phase II study of docetaxel plus cisplatin as second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 25: 2973-2977, 2005.
26. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS and Kang YK: A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 61: 631-637, 2008.
27. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK and Park SH: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13): 1513-1518, 2012.